Article
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Oncogene - 1 Jun 2018
Dankner Matthew, Rose April A N, Rajkumar Shivshankari, Siegel Peter M, Watson Ian R
Abstract excerpt
The RAS-RAF-MEK-ERK signaling cascade is among the most frequently mutated pathways in human cancer. Approximately 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase. FDA-approved combination therapies of BRAF and MEK inhibitors are available that provide survival benefits to patients with a BRAF V600 mutation. Non-V600 BRAF mutants are found in many cancers, and are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.